About this trial

This study aims to estimate the prevalence of Metabolic dysfunction - associated Steatoic liver disease (MASLD) among adults with primary hypothyroidism (overt or sub-clinical 1ry hypothyroidism) and prevalence of MASLD in Hashimoto-thyroiditis vs Euthyroid controls in non-diabetic patients.

Eligibility criteria

Qualifiers

Diagnosed with primary hypothyroidism (overt or sub clinical hypothyroidism) within 3 months with or without levothyroxine treatment.

Patients with positive antibody (positive TPO antibody or positive Thyroglobin antibody) irrespective of thyroid status

Metabolic dysfunction-associated steatotic liver disease (MASLD) assessment by ultrasound and Fibro-scan.

Disqualifiers

Diabetic patients according to American Diabetes Association (ADA) Criteria.

Excessive Alcohol consumption (> 30 gm/ day in men, 20 gm /day in women.

Body mass index (BMI) index >40 kg/m2

Other causes of chronic hepatic steatosis [e.g., positive hepatitis B virus (HBV), positive hepatitis C virus (HCV)), autoimmune disease, Wilson disease, drugs].

Trial design

Treatments tested in this trial

  • FibroScan
  • Thyroid Function Assessment

Treatment groups

200 Participants
are divided into 4 treatment groups

Locations

1
Sohag University82511, SohagSohag Governorate, Egypt

Sponsors and collaborators

Sohag University

Lead sponsor